Compare TG Therapeutics Inc (TGTX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Growth Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Vanguard Growth Index Fund ETF trades at $92 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 47.1× TG Therapeutics Inc's market cap, and Vanguard Growth Index Fund ETF is more actively traded (5,662,307 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| TGTX | VUG | |
|---|---|---|
Market Cap | $8.16B | $384.60B |
Volume | 1,735,121 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $92.64 |
52-Week Low | $26.94 | $70.00 |
Typical Hold Time | 16 Days | 47 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VUG trades at $92.42, down 0.24% on the day, with a bullish technical outlook supported by moving averages but showing overbought conditions on shorter-term RSI readings. The ETF maintains strong long-term performance credentials with 11-12% average annual returns since 2004, though current concentration in mega-cap tech stocks presents both opportunity and risk. Recent dividend activity shows minimal income generation with a $0.09 distribution scheduled for September 2026.
The growth-focused ETF offers exposure to market-leading companies but faces concentration risk with over 36% in three holdings. Long-term investors benefit from Vanguard's low-cost structure and historical outperformance, though near-term technical indicators suggest potential consolidation. Market sentiment remains positive for buy-and-hold strategies despite recent value stock outperformance in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
